| Name | Title | Contact Details |
|---|
Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.
THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.
Triad Technologies, Llc is a Englewood, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
onramp 113 is a Dixon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.